GGrantIndex
Sort

326,823 grants matching clinical trial

Duke Center for HIV Structural Biology

$5,412,818
Priyamvada Acharya · Duke University · U54 · FY2024 · AI

Enterprise for Research and Advocacy to Stop and Eradicate HIV (ERASE-HIV)

$5,412,341
Mirko Paiardini · Emory University · UM1 · FY2022 · AI

Cancer Center Support Grant

$5,410,051
Nancy E Davidson · University Of Pittsburgh At Pittsburgh · P30 · FY2010 · CA

Blood amyloid, tau, and neurodegeneration biomarkers and prediction of clinical onset, cognitive decline, and dementia diagnosis

$5,409,374
Randall J Bateman · Washington University · R01 · FY2025 · AG

UTMB CLINICAL AND TRANSLATIONAL SCIENCE AWARD

$5,407,519
Allan R. Brasier · University Of Texas Med Br Galveston · UL1 · FY2011 · RR

Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit

$5,406,746
Magdalena Elzbieta Sobieszczyk · Columbia University Health Sciences · UM1 · FY2020 · AI

Targeted Clinical Trial to Reduce the Risk of Antimicrobial Resistance

$5,405,643
Victor Yu · University Of Pittsburgh At Pittsburgh · N01 · FY2013 · AI

Molecular Targets Development Program

$5,405,638
James McMahon · Division Of Basic Sciences - Nci · ZIC · FY2009 · CA

Heart Failure Clinical Research Network Coordinating Center

$5,400,716
Kevin J Anstrom · Duke University · U10 · FY2016 · HL

Office of the Clinical Director

$5,400,014
Karran Phillips · National Institute On Drug Abuse · ZID · FY2017 · DA

HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP

$5,400,000
Fred Hutchinson Cancer Research Center · U01 · FY2005 · AI

PECRB-Research on Type 2 Diabetes Mellitus-Gila River Indian Reservation

$5,400,000
National Institute Of Diabetes And Digestive And Kidney Diseases · Y01 · FY2011 · DK

HIV PREVENTION TRIALS NETWORK LEADERSHIP GROUP

$5,400,000
Family Health International · U01 · FY2004 · AI

CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse

$5,400,000
Philip Iredale · Cerevel Therapeutics, Llc · UG3 · FY2021 · DA

Biomarkers of Cognitive Decline Among Normal Individuals: The Biocard Cohort

$5,399,026
Marilyn S Albert · Johns Hopkins University · U19 · FY2022 · AG

Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA

$5,397,843
Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

PREVENTION OF ALZHEIMER DEMENTIA & COGNITIVE DECLINE

$5,397,013
John C S Breitner · University Of Washington · U01 · FY2006 · AG

Convalescent Plasma to Limit Coronavirus Associated Complications: Randomized Blinded Phase 2 Study Comparing Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 Hospitalized Patients

$5,391,810
Ralph Lewis Sacco · University Of Miami School Of Medicine · UL1 · FY2020 · TR

COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT

$5,390,420
Duke University · P30 · FY2000 · CA

R-methadone-TAAP/MPAR: an abuse deterrent methadone prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial

$5,389,398
Lynn Kirkpatrick · Ensysce Biosciences, Inc. · UG3 · FY2019 · DA

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH

$5,387,719
S. Claiborne Johnston · University Of California, San Francisco · UL1 · FY2010 · RR

Hormone-Related Cancers

$5,387,445
Louise Brinton · Division Of Cancer Epidemiology And Genetics · ZIA · FY2014 · CA

SPRINT: Signature for Pain Recovery IN Teens

$5,386,781
Laura E Simons · Stanford University · R61 · FY2019 · NS

Disease Model Development and Phenotyping Project

$5,384,155
Gareth R Howell · Indiana University Indianapolis · U54 · FY2024 · AG

Disease Model Development and Phenotyping Project

$5,384,155
Gareth R Howell · Indiana University Indianapolis · U54 · FY2025 · AG